Loading asset research
Q3 2026 earnings · Nov 4
Adaptive Biotechnologies Corporation Common Stock
ADPTNasdaq · USD · StocksQuote as of · Exchange session not verified$29.45
+5.59%
Today
ADPT
Loading 1D prices…
Market cap
$4.7B
Volume
3.6M
52w high
$29.5852w low
$12.00Company profile
Adaptive Biotechnologies Corporation Common Stock
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Seattle, WA, United States
Employees
624
Fiscal year end
1231
CIK
1478320
Session & valuation
Open$28.00
Previous close$27.89
Day high$29.58
Day low$27.50
30-day avg. volume2M
Outstanding shares159.6M
Diluted EPS-$0.39
Latest annual period
P/E (trailing)-75.51
P/E (forward)-162.59
Price / book32.93
Beta2.10
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| IOVAIovance Biotherapeutics Inc. Common Stock | $4.9B | $263.5M | -148.39% | -$1.09 | +8.74% | Buy |
| CRSPCRISPR Therapeutics AG Common Shares | $5.4B | $3.5M | -16569.77% | -$6.47 | -1.56% | Buy |
| RLAYRelay Therapeutics Inc. Common Stock | $3.9B | $15.4M | -1800.58% | -$1.61 | -3.08% | Buy |
| SRRKScholar Rock Holding Corporation Common Stock | $5.9B | $0.00 | — | -$3.29 | -2.37% | Buy |
| CGONCG Oncology Inc. Common stock | $6.1B | $4M | -3985.15% | -$2.08 | -7.54% | Buy |